<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04172792</url>
  </required_header>
  <id_info>
    <org_study_id>TOLCAL</org_study_id>
    <nct_id>NCT04172792</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability Ultra-high-caloric Food Supplements in Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>TOLCAL</acronym>
  <official_title>Safety and Tolerability of Fat-rich vs. Carbohydrate-rich High-caloric Food Supplements in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Christian Ludolph, Prof.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nutritia GmbH, 91052 Erlangen, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ulm</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LIPCAL-ALS study (NCT02306590) has provided preliminary evidence that a high-caloric
      nutrition might prolong survival in fast-progressing ALS patients. Since increasing the
      amount of calories of the intervention might possibly increase the beneficial effect, the
      investigators seek to investigate whether an ultra-high caloric diet (UHCD), featuring the
      double amount of calories compared to LIPCAL-ALS, will be well tolerated by ALS patients and
      may serve as an intervention for a potential LIPCALII study. For this purpose, the
      investigators will compare two different UHCDs (one fat-rich and one carbohydrate-rich) with
      regard to safety and tolerability over a time frame of 4 weeks. A third group will receive
      the original diet from LIPCAL, and a fourth group will receive no intervention (control
      group).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2019</start_date>
  <completion_date type="Anticipated">November 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of Adverse Events and Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory values</measure>
    <time_frame>4 weeks</time_frame>
    <description>Incidence of abnormalities in clinical laboratory assessments, vital signs and physical examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Appetite</measure>
    <time_frame>2 weeks; 4 weeks</time_frame>
    <description>Change of Appetite-Score (Council of Nutrition appetite questionnaire, CNAQ) compared to baseline; values 8-40; higher values mean better appetite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eating Habits</measure>
    <time_frame>2 weeks; 4 weeks</time_frame>
    <description>Change in eating habits as evaluated by a standardized questionnaire (Ulmer eating habits questionnaire); descriptive information and evaluation; no overall score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Taste of Intervention</measure>
    <time_frame>2 weeks; 4 weeks</time_frame>
    <description>taste of intervention (visual analogous scale); values 1-9, higher values mean better taste</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight</measure>
    <time_frame>2 weeks; 4 weeks</time_frame>
    <description>change of body weight compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>4 weeks</time_frame>
    <description>change of neurofilament light chains (NfL) in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Incidence of Adverse Events and Serious Adverse Events (evaluation via phone call 2 weeks after intervention was finished)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALSFRS-R</measure>
    <time_frame>4 weeks</time_frame>
    <description>change of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) compared to baseline; values 0-48; higher values mean less impairment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>high-caloric fatty diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intake of 405 kcal (45g fat) per day in addition to normal food intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultra-high-caloric fatty diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intake of 810 kcal (90g fat) per day in addition to normal food intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ultra-high-caloric carbohydrate-rich diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intake of 900 kcal (111.4g carbohydrate, 34.9g fat, 36.0g protein) in addition to normal food intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>normal food intake (no intervention)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>high-caloric fatty diet</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>high-caloric fatty diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ultra-high-caloric fatty diet</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>ultra-high-caloric fatty diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>ultra-high-caloric carbohydrate-rich diet</intervention_name>
    <description>see arm/group description</description>
    <arm_group_label>ultra-high-caloric carbohydrate-rich diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Amyotrophic Lateral Sclerosis (ALS) according to the revised version of
             the El Escorial criteria (Ludolph et al. 2015)

          -  Slope of ALS Functional Rating Scale Revised (ALSFRS-R) of &gt;0.25 points per month at
             baseline visit based on the formula (48 - score at baseline visit) / (time between
             date of first symptom and baseline visit)

          -  stable on standard therapy riluzole (100 mg/day) for at least 4 weeks

          -  capable of thoroughly understanding all information given and giving full informed
             consent according to good clinical practice (GCP)

        Exclusion Criteria:

          -  already taking any dietary supplements

          -  participation in another clinical trial within the preceding 8 weeks

          -  tracheostomy or assisted ventilation of any type which exceeds 23 hours per day

          -  pregnancy or breast-feeding females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johannes Dorst, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ulm</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Dorst, PD Dr.</last_name>
    <phone>+49 731 177 5285</phone>
    <email>johannes.dorst@uni-ulm.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joachim Schuster, PhD</last_name>
    <phone>+49 731 500 63000</phone>
    <email>joachim.schuster@uni-ul.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Ulm, Department of Neurology</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wurttemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Dorst, PD Dr.</last_name>
      <phone>+49 731 177 5285</phone>
      <email>johannes.dorst@uni-ulm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J; WFN Research Group On ALS/MND. A revision of the El Escorial criteria - 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):291-2. doi: 10.3109/21678421.2015.1049183. Epub 2015 Jun 29.</citation>
    <PMID>26121170</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Ulm</investigator_affiliation>
    <investigator_full_name>Albert Christian Ludolph, Prof.</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be available beginning 3 months and ending 5 years following article publication. Data will be shard with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data acess agreement. The study protocol will be available for 5 years at htpps://www.uniklinik-ulm.de/neurologie.html.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>3 month after publication until 5 years after publication</ipd_time_frame>
    <ipd_access_criteria>Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal. Proposals should be directed to johannes.dorst@uni-ulm.de; to gain access, data requestors will need to sign a data acess agreement.</ipd_access_criteria>
    <ipd_url>https://www.uniklinik-ulm.de/neurologie.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

